A1M Pharma AB has changed its name to Guard Therapeutics International AB
The scientific concept is to reinforce the body's own defense mechanism against diseases caused by pathologic oxidative stress.
A1M (Alpha-1-Microglobulin) is an endogenous protein that is designed to continuously remove toxic substances arising from oxidative stress, including ROS (Reactive Oxygen Species). These substances would otherwise cause severe inflammation and damage to cells and tissue of our bodies. Our drug candidate, ROSgard is a recombinant version of the A1M protein that can be used in therapeutic settings. Just like A1M, ROSgard is naturally designed to ”target” the kidneys, and hence to be in place when the kidneys are subjected to oxidative stress. Treatment with ROSgard has the potential to save lives and prevent both acute and chronic kidney injuries, where the reduced kidney function could otherwise lead to severe consequences, such as need for dialysis treatment.
The scientific concept is based upon more than 40 years of work by a group of internationally leading scientists at Lund University, Sweden. The scientists have shown that A1M prevents oxidative stress-related damage by utilizing the body’s key defense mechanisms.
Figure: Model showing how ROSgard protects against acute kidney injury in the context of open-heart surgery. ROSgard binds to and neutralizes both ROS and heme before they can damage the kidneys. In addition, ROSgard “targets” the kidneys and prevents acute kidney injury by protecting, cleaning and repairing tissues and cells already exposed to oxidative stress. In summary by using a wide range of mechanisms ROSgard provide a robust protection of the kidneys.
About us and our operating activities.Read more